Saori Takahashi
Hondo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy.
Journal: Cancer chemotherapy and pharmacology
Published: December 08, 2021
Refractory Watery Diarrhea Due to an End-Stage Vasoactive Intestinal Peptide Production Tumor Treated with Opium Tincture-A Case Report
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: November 01, 2020
Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.
Journal: Scientific reports
Published: October 20, 2020
Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia.
Journal: Journal of clinical pharmacy and therapeutics
Published: July 21, 2020
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
Journal: International journal of hematology
Published: July 12, 2020
Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.
Journal: Medical oncology (Northwood, London, England)
Published: April 10, 2018
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.
Journal: Haematologica
Published: April 04, 2018
Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.
Journal: Experimental hematology & oncology
Published: January 31, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026